Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | GGT1 | P19440 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768440 | 1.00 | GFPT1 (0.46) | GFPT1SLC7A5PMP22CASRPTGS1 | |
| SCHEMBL1768767 | 0.81 | OTC (0.46) | PMP22GGT1 | |
| SCHEMBL1768764 | 0.81 | OTC (0.46) | PMP22GGT1 | |
| SCHEMBL1768761 | 0.81 | GFPT1 (0.44) | GFPT1SLC7A5PMP22CASR | |
| SCHEMBL1768765 | 0.81 | GFPT1 (0.44) | GFPT1SLC7A5PMP22CASR | |
| SCHEMBL1768908 | 0.79 | GFPT1 (0.49) | GFPT1SLC7A5PMP22CASRPTGS1 | |
| SCHEMBL1768905 | 0.79 | GFPT1 (0.49) | GFPT1SLC7A5PMP22CASRPTGS1 | |
| SCHEMBL13585097 | 0.78 | GFPT1 (0.45) | GFPT1SLC7A5PMP22CASR | |
| SCHEMBL13585101 | 0.78 | GFPT1 (0.45) | GFPT1SLC7A5PMP22CASR | |
| SCHEMBL17852316 | 0.78 | GFPT1 (0.41) | GFPT1CASRPTGS1SLC7A11GGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | GFPT1 3069/4885SLC7A5 1767/4885PMP22 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.